Individualized treatment planning in oncology: Role of PET and radiolabelled anticancer drugs in predicting tumour resistance

Current Pharmaceutical Design

Volumn 14, Issue 28, 2008, Pages 2914-2931

  van der Veldt, Astrid A M ^a   Luurtsema, Gert ^a   Lubberink, Mark ^a   Lammertsma, Adriaan A ^a   Hendrikse, N Harry ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fluoropaclitaxel; Fluorouracil; Oncology; PET; Radiolabelled Anticancer Drugs; Tumour

Indexed keywords

3' FLUOROTHYMIDINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BROMINE 76; CAPECITABINE; CARBON 11; CARMUSTINE; CISPLATIN; COPPER 64; CYCLOPHOSPHAMIDE; DASATINIB; DAUNORUBICIN; DOCETAXEL; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOLINIUM; GEFITINIB; HORMONE RECEPTOR; IODINE 124; MONOCLONAL ANTIBODY; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; NITROGEN 13; PACLITAXEL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; WATER O 15; XR 5000; YTTRIUM 86; ZIRCONIUM; DIAGNOSTIC AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED TOMOGRAPHY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; INDIVIDUALIZATION; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPY DELAY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VASCULARIZATION; ANIMAL; DRUG RESISTANCE; METHODOLOGY; NEOPLASM; SCINTISCANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; ISOTOPE LABELING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 50249142684     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786404344     Document Type: Review

References (198)

1. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25: 1760-4.
2. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-9.
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
4. Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HY, Kim JS, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol (Meeting Abstracts) 2007; 25: 3546.
5. Flaherty KT. Sorafenib in renal cell carcinoma. Clin Cancer Res 2007; 13: 747s-52s.
6. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 2007; 8: 975-84.
7. Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Bex A, De Gast G, Haanen JB, et al. Sunitinib for treatment of advanced renal cell cancer: Primary tumor response. Clin Cancer Res 2008; 14: 2431-6.
8. Vanel D, Albiter M, Shapeero L, Le Cesne A, Bonvalot S, Le Pechoux C, et al. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: A prospective study of 54 patients. Eur J Radiol 2005; 54: 118-23.
9. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato dP, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001; 358: 1421-3.
10. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45: 17-21.
11. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-20.
12. Herrmann K, Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007; 13: 3552-8.
13. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006; 8: 36-42.
14. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: Form and function. Radiology 2007; 242: 360-85.
15. Diksic M, Sako K, Feindel W, Kato A, Yamamoto YL, Farrokhzad S, et al. Pharmacokinetics of positron-labeled 1,3-Bis(2-chloro-ethyl)nitrosourea in human brain tumors using positron emission tomography. Cancer Res 1984; 44: 3120-4.
16. Freed BR, McQuinn RL, Tilbury RS, Digenis GA. Distribution of 13N in rat tissues following intravenous administration of nitroso-labeled BCNU. Cancer Chemother Pharmacol 1982; 10: 16-21.
17. Tyler JL, Yamamoto YL, Diksic M, Theron J, Villemure JG, Worthington C, et al. Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. J Nucl Med 1986; 27: 775-80.
18. Kalen JD, Hirsch JI, Kurdziel KA, Eckelman WC, Kiesewetter DO. Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]-Paclitaxel (FPAC). Appl Radiat Isot 2007; 65: 696-700.
19. Kiesewetter DO, Jagoda EM, Kao CH, Ma Y, Ravasi L, Shimoji K, et al. Fluoro-, bromo-, and iodopaclitaxel derivatives: Synthesis and biological evaluation. Nucl Med Biol 2003; 30: 11-24.
20. Ravert HT, Klecker RW, Collins JM, Mathews WB, Pomper MG, Wahl RL, et al. Radiosynthesis of [11C]paclitaxel. J Label Compd Radiopharm 2002; 45: 471-477.
21. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, et al. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 2005; 46: 1866-71.
22. Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J, et al. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. J Nucl Med 2006; 47: 1995-9.
23. Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Agarwal R, Barrett D, et al. Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nucl Med Biol 2007; 34: 823-31.
24. Fowler JS, Finn RD, Lambrecht RM, Wolf AP. The synthesis of 18 F-5-fluorouracil. VII. J Nucl Med 1973; 14: 63-4.
25. Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Extraction of 5-fluorouracil by tumor and liver: A noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001; 61: 4937-41.
26. Bading JR, Alauddin MM, Fissekis JD, Shahinian AH, Joung J, Spector T, et al. Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. J Nucl Med 2000; 41: 1714-24.
27. Bading JR, Yoo PB, Fissekis JD, Alauddin MM, D'Argenio DZ, Conti PS. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: A positron emission tomography study in rats. Cancer Res 2003; 63: 3667-74.
28. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Irngartinger G, Oberdorfer F, et al. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1998; 39: 465-73.
29. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mohler M, Oberdorfer F, et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998; 39: 1197-202.
30. Dimitrakopoulou A, Strauss LG, Clorius JH, Ostertag H, Schlag P, Heim M, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1993; 34: 1075-81.
31. Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R, et al. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res 2006; 12: 3115-23.
32. Harte RJ, Matthews JC, O'Reilly SM, Price PM. Sources of error in tissue and tumor measurements of 5-[18F]fluorouracil. J Nucl Med 1998; 39: 1370-6.
33. Harte RJ, Matthews JC, O'Reilly SM, Tilsley DW, Osman S, Brown G, et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-Laspartate, folinic acid, and interferon alfa. J Clin Oncol 1999; 17: 1580-8.
34. Hohenberger P, Strauss LG, Lehner B, Frohmuller S, Dimitrakopoulou A, Schlag P. Perfusion of colorectal liver metastases and uptake of fluorouracil assessed by H2(15)O and [18F]uracil positron emission tomography (PET). Eur J Cancer 1993; 29A: 1682-6.
35. Kissel J, Brix G, Bellemann ME, Strauss LG, Dimitrakopoulou-Strauss A, Port R, et al. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997; 57: 3415-23.
36. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998; 83: 245-53.
37. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 2000; 355: 2125-31.
38. Shani J, Wolf W. A model for prediction of chemotherapy response to 5-fluorouracil based on the differential distribution of 5-[18F]fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res 1977; 37: 2306-8.
39. Visser GW, Van der Wilt CL, Wedzinga R, Peters GJ, Herscheid JD. 18F-radiopharmacokinetics of [18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: A study for a correlation with oncological results. Nucl Med Biol 1996; 23: 333-42
40. Lubberink M, Schneider H, Bergstrom M, Lundqvist H. Quantitative imaging and correction for cascade gamma radiation of 76Br with 2D and 3D PET. Phys Med Biol 2002; 47: 3519-34.
41. Perk LR, Visser OJ, Stigter-Van Walsum M, Vosjan MJWD, Visser GWM, Zijlstra JM, et al. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33: 1337-45.
42. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003; 63: 2409-15.
43. Ginos JZ, Cooper AJ, Dhawan V, Lai JC, Strother SC, Alcock N, et al. [13N]cisplatin PET to assess pharmacokinetics of intraarterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 1987; 28: 1844-52.
44. Kesner AL, Hsueh WA, Htet NL, Pio BS, Czernin J, Pegram MD, et al. Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. J Nucl Med 2007; 48: 2021-7.
45. Osman S, Luthra SK, Brady F, Hume SP, Brown G, Harte RJ, et al. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. Cancer Res 1997; 57: 2172-80.
46. Osman S, Rowlinson-Busza G, Luthra SK, Brown GD, Brady F, Ranicar A, et al. Biodistribution and metabolism of [4-carbonyl-11C]temozolomide in nude mice bearing human tumour xenografts of glioma and non-melanotic melanoma. J Label Compd Radiopharm 1999; 42: S704-S706.
47. Osman S, Rowlinson-Busza G, Luthra SK, Aboagye EO, Brown GD, Brady F, et al. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues. Cancer Res 2001; 61: 2935-44.
48. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-6.
49. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, et al. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008.
50. Van der Veldt AA, Lammertsma AA, Hendrikse NH. [11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics. Clin Cancer Res 2007; 13: 7522-3.
51. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of 64Cu-labeled Abegrin(trademark), a humanized monoclonal antibody against integrin (alpha)v(beta)3. Cancer Res 2006; 66: 9673-81.
52. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007; 34: 850-8.
53. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: Preliminary study. Cancer Biother Radiopharm 1996; 11: 235-45.
54. Nagengast WB, De Vries EG, Hospers GA, Mulder NH, De Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48: 1313-9.
55. Saleem A, Harte RJ, Matthews JC, Osman S, Brady F, Luthra SK, et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 2001; 19: 1421-9.
56. Solbach C, Patt M, Reimold M, Blocher A, Dohmen BM, Bares R, et al. [11C]Vinblastine syntheses and preliminary imaging in cancer patients. J Pharm Pharm Sci 2007; 10: 266s-76s.
57. Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med 2007; 48: 1017-20.
58. Fenner MH, Possinger K. Chemotherapy for breast cancer brain metastases. Onkologie 2002; 25: 474-9.
59. Helgason HH, Mallo HA, Droogendijk H, Haanen JG, Van der Veldt AA, Van den Eertwegh AJ, et al. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol 2008; 26: 152-4.
60. Bart J, Nagengast WB, Coppes RP, Wegman TD, Van der Graaf WTA, Groen HJM, et al. Irradiation of rat brain reduces Pglycoprotein expression and function. Br J Cancer 2007; 97: 322-6.
61. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, et al. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin Imaging 1997; 21: 332-6.
62. Buxton I. In: Brunton L Ed, Goodman & Filman's The pharmacological basis of therapeutics. Chicago, McGraw-Hill, 2005; 1-39.
63. Trynda-Lemiesz L, Luczkowski M. Human serum albumin: Spectroscopic studies of the paclitaxel binding and proximity relationships with cisplatin and adriamycin. J Inorg Biochem 2004; 98: 1851-6.
64. Dumez H, Guetens G, De Boeck G, Highley MS, De Bruijn EA, Van Oosterom AT, et al. In vitro partition of docetaxel and gemcitabine in human volunteer blood: The influence of concentration and gender. Anticancer Drugs 2005; 16: 885-91.
65. Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, et al. A general method to correct PET data for tissue metabolites using a dual-scan approach. J Nucl Med 2000; 41: 706-11.
66. Luthra SK, Osman S, Hume S, Tilsley DWO, Vaja V, Brown G, et al. 5-[18F]flurouracil - The problem of metabolites in tissue. J Label Compd Radiopharm 1994; 35: 565-6.
67. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
68. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
69. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
70. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
71. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-13.
72. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
73. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors. Clin Cancer Res 2007; 13: 2804-10.
74. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
75. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7
76. Batchelor TT, Sorensen AG, Di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
77. McDonald DM, Choyke PL. Imaging of angiogenesis: From microscope to clinic. Nat Med 2003; 9: 713-25.
78. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005; 46: 1333-41.
79. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006; 12: 3942-9.
80. Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006; 47: 763-9.
81. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 6610-6.
82. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P, et al. Patterns of {alpha}v{beta}3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET. J Nucl Med 2008; 49: 255-9.
83. Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 2004; 3: 96-104.
84. Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004; 31: 1081-9.
85. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005; 2: E70.
86. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007; 48: 1162-71.
87. Li ZB, Wu Z, Chen K, Chin FT, Chen X. Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem 2007; 18: 1987-94.
88. Ogawa M, Hatano K, Oishi S, Kawasumi Y, Fujii N, Kawaguchi M, et al. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta3 integrin related tumor imaging. Nucl Med Biol 2003; 30: 1-9.
89. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. MicroPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 2005; 46: 1707-18
90. Wu Z, Li ZB, Chen K, Cai W, He L, Chin FT, et al. MicroPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 2007; 48: 1536-44.
91. Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47: 2048-56.
92. Wang H, Cai W, Chen K, Li ZB, Kashefi A, He L, et al. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 2007; 34: 2001-10.
93. Beaney RP, Lammertsma AA, Jones T, McKenzie CG, Halnan KE. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1984; 1: 131-4.
94. Frackowiak RS, Jones T, Lenzi GL, Heather JD. Regional cerebral oxygen utilization and blood flow in normal man using oxygen-15 and positron emission tomography. Acta Neurol Scand 1980; 62: 336-44.
95. 15O-PET and DCE-MRI to measure tumor blood flow. Oncologist 2008; 13: 631-44.
96. Herscovitch P, Markham J, Raichle ME. Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. J Nucl Med 1983; 24: 782-9.
97. Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res 2002; 8: 2109-15.
98. Kubo S, Yamamoto K, Magata Y, Iwasaki Y, Tamaki N, Yonekura Y, et al. Assessment of pancreatic blood flow with positron emission tomography and oxygen-15 water. Ann Nucl Med 1991; 5: 133-8.
99. Lehtio K, Oikonen V, Gronroos T, Eskola O, Kalliokoski K, Bergman J, et al. Imaging of blood flow and hypoxia in head and neck cancer: Initial evaluation with [15O]H2O and [18F]Fluoroery-thronitroimidazole PET. J Nucl Med 2001; 42: 1643-52.
100. Lodge MA, Carson RE, Carrasquillo JA, Whatley M, Libutti SK, Bacharach SL. Parametric images of blood flow in oncology PET studies using [15O]water. J Nucl Med 2000; 41: 1784-92.
101. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method. Cancer Res 1992; 52: 1592-7.
102. Schuster DP, Markham J, Welch MJ. Positron emission tomography measurements of pulmonary vascular permeability with Ga-68 transferrin or C-11 methylalbumin. Crit Care Med 1998; 26: 518-25.
103. Brooks DJ, Frackowiak RS, Lammertsma AA, Herold S, Leenders KL, Selwyn AP, et al. A comparison between regional cerebral blood flow measurements obtained in human subjects using 11C-methylalbumin microspheres, the C15O2 steady-state method, and positron emission tomography. Acta Neurol Scand 1986; 73: 415-22.
104. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996; 56: 5522-8.
105. Bhattacharya A, Toth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, et al. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res 2004; 10: 8005-17.
106. Bonn D. Why do hypoxic cells behave badly? Lancet Oncol 2000; 1: 202
107. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
108. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006; 24: 2098-104.
109. Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006; 47: 410-8.
110. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-60.
111. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 2004; 45: 1851-9.
112. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69: 541-51.
113. Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: A pilot study. Eur J Nucl Med Mol Imaging 2007; 34: 1566-75.
114. Lehtio K, Oikonen V, Gronroos T, Eskola O, Kalliokoski K, Bergman J, et al. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluo-roerythronitroimidazole PET. J Nucl Med 2001; 42: 1643-52.
115. Lehtio K, Oikonen V, Nyman S, Gronroos T, Roivainen A, Eskola O, et al. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 2003; 30: 101-8.
116. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 59: 971-82.
117. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003; 55: 1233-8.
118. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003; 30: 844-50.
119. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008; 49: 201-5.
120. Serganova I, Doubrovin M, Vider J, Ponomarev V, Soghomonyan S, Beresten T, et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 2004; 64: 6101-8.
121. Ebos JML, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104: 17069-74.
122. Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, et al. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol 2003; 21: 203-10.
123. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001; 42: 213-21.
124. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006; 33: 460-6.
125. Lubberink M, Tolmachev V, Widstrom C, Bruskin A, Lundqvist H, Westlin JE. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. J Nucl Med 2002; 43: 1391-7.
126. Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, et al. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: Biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. Journal of nuclear medicine : Official publication, Society of Nuclear Medicine 2006; 47: 566-73.
127. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: Biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008; 35: 72-9.
128. Wester HJ, Brockmann J, Rosch F, Wutz W, Herzog H, Smith-Jones P, et al. PET-pharmacokinetics of 18F-Octreotide: A comparison with 67Ga-DFO- and 86Y-DTPA-octreotide. Nucl Med Biol 1997; 24: 275-86.
129. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006; 24: 2793-9.
130. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]-Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996; 2: 933-9.
131. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19: 2797-803.
132. Dehdashti F, McGuire AH, Van Brocklin HF, Siegel BA, Andriole DP, Griffeth LK, et al. Assessment of 21-[18F]fluoro-16 alphaethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 1991; 32: 1532-7.
133. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32: 344-50.
134. Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 2004; 45: 1966-71.
135. Garg S, Doke A, Black KW, Garg PK. In vivo biodistribution of an androgen receptor avid PET imaging agent 7-alpha-fluoro-17 alpha-methyl-5-alpha-dihydrotestosterone ([(18)F]FMDHT) in rats pretreated with cetrorelix, a GnRH antagonist. Eur J Nucl Med Mol Imaging 2008; 35: 379-85.
136. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
137. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
138. Dijkers E, Lub-de Hooge MN, Kosterink JG, Jager PL, Brouwers AH, Perk LR, et al. Characterization of 89Zr-trastuzumab for clinical HER2 immunoPET imaging. J Clin Oncol (Meeting Abstracts) 2007; 25: 3508.
139. Mume E, Orlova A, Malmstrom PU, Lundqvist H, Sjoberg S, Tolmachev V. Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridine-carboxylate, a potential label for immunoPET. Nucl Med Biol 2005; 32: 613-22.
140. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62.
141. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, et al. Human multidrug-resistant cell lines: Increased mdr1 expression can precede gene amplification. Science 1986; 232: 643-5.
142. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159-64.
143. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues. Proc Natl Acad Sci 1987; 84: 7735-8.
144. Elsinga PH, Franssen EJ, Hendrikse NH, Fluks L, Weemaes AM, Van der Graaf WT, et al. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med 1996; 37: 1571-5.
145. Hendrikse NH, De Vries EG, Eriks-Fluks L, Van der Graaf WT, Hospers GA, Willemsen AT, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999; 59: 2411-6.
146. Luurtsema G, Molthoff CFM, Windhorst AD, Smit JW, Keizer H, Boellaard R, et al. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: In vitro and in vivo evaluation. Nucl Med Biol 2003; 30: 747-51.
147. Luurtsema G, Molthoff CFM, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJF. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: Kinetics and metabolism in the rat. Nucl Med Biol 2005; 32: 87-93.
148. Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV, Thomas R, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-83.
149. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier-Borst W, Van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22: 434-42.
150. Bigott HM, Prior JL, Piwnica-Worms DR, Welch MJ. Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi. Mol Imaging 2005; 4: 30-9.
151. Luurtsema G, Windhorst AD, Mooijer MPJ, Herscheid JDM, Lammertsma AA, Franssen EJF. Fully automated high yield synthesis of (R)- and (S)-[11C]verapamil for measuring P-glycoprotein function with positron emission tomography. J Label Compd Radiopharm 2002; 45: 1199-207.
152. Kothari PJ, Finn RD, Larson SM. Syntheses of colchicine and isocolchicine labelled with carbon-11 or carbon-13. J Label Compd Radiopharm 1995; 36: 521-8.
153. Levchenko A, Mehta BM, Lee JB, Humm JL, Augensen F, Squire O, et al. Evaluation of 11C-colchicine for PET imaging of multiple drug resistance. J Nucl Med 2000; 41: 493-501.
154. Eriks-Fluks E, Elsinga PH, Hendrikse NH, Franssen EJ, Vaalburg W. Enzymatic synthesis of [4-methoxy-11C]daunorubicin for functional imaging of P-glycoprotein with PET. Appl Radiat Isot 1998; 49: 811-3.
155. Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, et al. 11C-Loperamide and Its N-Desmethyl Radiometabolite Are Avid Substrates for Brain Permeability-Glycoprotein Efflux. J Nucl Med 2008; 49: 649-56.
156. Hendrikse NH, Schinkel AH, De Vries EG, Fluks E, Van der Graaf WT, Willemsen AT, et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 1998; 124: 1413-8.
157. Hendrikse NH, Bart J, De Vries EG, Groen HJ, Van der Graaf WT, Vaalburg W. P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography. J Clin Pharmacol 2001; Suppl: 48S-54S.
158. Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 2007; 109: 924-32.
159. Dunn TJ, Braun RD, Rhemus WE, Rosner GL, Secomb TW, Tozer GM, et al. The effects of hyperoxic and hypercarbic gases on tumour blood flow. Br J Cancer 1999; 80: 117-26.
160. Suzuki M, Hori K, Abe I, Saito S, Sato H. A new approach to cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 1981; 67: 663-9.
161. Flower MA, Zweit J, Hall AD, Burke D, Davies MM, Dworkin MJ, et al. 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur J Nucl Med 2001; 28: 99-103.
162. Koh T, Taniguchi H, Yamagishi H. Oxygen-15 positron-emission tomography for predicting selective delivery of a chemotherapeutic agent to hepatic cancers during angiotensin II-induced hypertension. Cancer Chemother Pharmacol 2003; 51: 349-58.
163. Taniguchi H, Koyama H, Masuyama M, Takada A, Mugitani T, Tanaka H, et al. Angiotensin-II-induced hypertension chemotherapy: Evaluation of hepatic blood flow with oxygen-15 PET. J Nucl Med 1996; 37: 1522-3.
164. Chowdhury S, Spicer J F, Harper P G. Hypertension and targeted therapy. Part 2: Small molecule inhibitors of VEGF. Target Oncol 2006; 1: 172-178.
165. Chowdhury S, Spicer J F, Harper P G. Hypertension and targeted therapy. Part 1: Bevacizumab. Target Oncol 2006; 1: 104-108.
166. Van Cruijsen H, Van der Veldt AA, Hoekman K. Tyrosine kinase inhibitors of VEGF receptors: Clinical issues and unanswered questions. Front Biosci 2008; in press.
167. Van der Veldt AA, Van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol 2007; 18: 1747-50.
168. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CYC, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-50.
169. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-73.
170. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-6.
171. Diksic M, Farrokhzad S, Yamamoto L, Feindel W. Synthesis of 'no carrier added' 1,3-bis-(2-chloroethyl)nitrosourea (BCNU). J Nucl Med 1982; 23: 895-8.
172. Diksic M, Jolly D, Farrokhzad S. An on-line synthesis of 'no-carrier-added' [11C]phosgene. Int J Nucl Med Biol 1982; 9: 283-5.
173. Sako K, Diksic M, Farrokhzad S, Yamamoto YL, Feindel W. Pharmacokinetics of 11C-BCNU in experimental brain tumor. J Neurooncol 1985; 3: 229-35
174. Mitsuki S, Diksic M, Conway T, Yamamoto YL, Villemure JG, Feindel W. Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET. J Neurooncol 1991; 10: 47-55.
175. Pettit WA, Tilbury RS, Digenis GA, Mortara RH. A convenient synthesis of 13N BCNU. J Label Compd Radiopharm 1977; 13: 119-22.
176. Haber MT, Cooper AJL, Rosenspire KC. Synthesis of [13N]cisplatin. J Label Compd Radiopharm 1985; 22: 509-16.
177. Lacan G, Kesner AL, Gangloff A, Zheng L, Czernin J, Melega WP, et al. Synthesis of 2-(2-chloro-2′-[18F]fluoroethyl)amino]-2H-1, 3,2-oxazaphosphorinane-2-oxide (18F-fluorocyclophosphamide), a potential tracer for breast tumor prognostic imaging with PET. J Label Compd Radiopharm 2005; 48: 635-43.
178. Brown GD, Turton DR, Luthra SK, Price P, Jones T, Stevens MFG, et al. Synthesis of [11C-methyl]methylisocyanate and application with microwave heating to labelling the novel anticancer agent temozolomide. J Label Compd Radiopharm 1994; 35: 100-2.
179. Brown GD, Luthra SK, Brock CS, Stevens MFG, Price PM, Brady F. Antitumor imidazotetrazines. 40. Radiosyntheses of [4-11C-carbonyl]- and [3-N-11C-methyl]-8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) for positron emission tomography (PET) studies. J Med Chem 2002; 45: 5448-57.
180. Van Tilburg EW, Franssen EJF, Van der Hoeven JJM, Van der Meij M, Elshove D, Lammertsma AA, et al. Radiosynthesis of [11C]docetaxel. J Label Compd Radiopharm 2004; 47: 763-77.
181. Fei X, Wang JQ, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl Med Biol 2004; 31: 1033-41.
182. Seki K, Nishijima K, Kuge Y, Tamaki N, Wiebe LI, Ohkura K. A novel and efficient synthesis of [2-11C]5-fluorouracil for prognosis of cancer chemotherapy. J Pharm Pharm Sci 2007; 10: 212-6.
183. Brown G, Brady F, Roberts AD, Osman S, Luthra SK, Price PM. Improved radiosynthesis of 5-[18F]fluorouracil. J Label Compd Radiopharm 1999; 42: S533-S535.
184. Oberdorfer F, Hofmann E, Maier-Borst W. Preparation of 18F-labelled 5-fluorouracil of very high purity. J Label Compd Radiopharm 1989; 27: 137-45.
185. Brady F, Luthra SK, Brown G, Osman S, Harte RJ, Denny WA, et al. Carbon-11 labelling of the antitumour agent N-[2-(dimethyl- amino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man. Appl Radiat Isot 1997; 48: 487-92.
186. Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, et al. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 2007; 50: 5853-7.
187. Wang JQ, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 2006; 16: 4102-6.
188. Kil KE, Ding YS, Lin KS, Alexoff D, Kim SW, Shea C, et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 2007; 34: 153-63.
189. Wang JQ, Miller KD, Sledge GW, Zheng QH. Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett 2005; 15: 4380-4.
190. Seimbille Y, Benard F, Rousseau J, Pepin E, Aliaga A, Tessier G, et al. Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16alpha-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol 2004; 31: 691-8.
191. Shani J, Gazit A, Livshitz T, Biran S. Synthesis and receptor-binding affinity of fluorotamoxifen, a possible estrogen-receptor imaging agent. J Med Chem 1985; 28: 1504-11.
192. Yang DJ, Wallace S, Tansey W, Wright KC, Kuang LR, Tilbury RS, et al. Synthesis and in vitro receptor binding studies of fluorotamoxifen analogues. Pharm Res 1991; 8: 174-7.
193. Verel I, Visser GW, Boerman OC, Van Eerd JE, Finn R, Boellaard R, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003; 18: 655-61.
194. Perk LR, Visser GWM, Vosjan MJWD, Stigter-Van Walsum M, Tijink BM, Leemans CR, et al. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46: 1898-906.
195. Winberg KJ, Persson M, Malmstrom PU, Sjoberg S, Tolmachev V. Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]unde- cahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. Nucl Med Biol 2004; 31: 425-33.
196. Chikuma M, Sato T, Komeda S. Current status of and future perspectives for platinum antitumor drugs. Yakugaku Zasshi 2008; 128(3): 307-16.
197. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008; 14(11): 1049-57.
198. Wagner CC, Muller M, Lappin G, Langer O. Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel 2008; 11(1): 104-10.